Aktana Acquires Tact.ai’s Field Engagement and Conversational AI Technology
1.11.2023 17:00:00 EET | Business Wire | Press release
Aktana, Inc., the leader in intelligent customer engagement for the global life sciences industry, today announced the acquisition of Tact.ai’s field engagement and conversational AI technology. The addition extends Aktana’s leadership in field intelligence by delivering several new capabilities frequently requested by commercial and medical leaders overseeing omnichannel programs:
- Real-time delivery of suggestions and insights on the mobile phone
- Pervasive and on-demand recommendations throughout the user experience, including a conversational AI assistant
- Richer engagement data to improve AI recommendations
“Today’s sales rep or MSL is being asked to do more in less time and with fewer resources than ever before, and they need immediate access to the best intelligence on their most preferred device, the mobile phone,” said John Vitalie, CEO, Aktana. “Adding aspects of Tact.ai’s mobile technology and easy-to-use interface to the Aktana portfolio will accelerate our customers’ efforts to create the next-generation field force, one that’s powered by intelligence and adept at using any channel to support their HCPs.”
“Tact.ai set out to build human-friendly technology that connects life science companies and their customers, to help patients who can't wait,” said Chuck Ganapathi, CEO, Tact.ai. “Critical to that mission is a system of intelligence that fuels every interaction. As the pioneer of this category and with Tact.ai’s technology, Aktana is now even better positioned to lead this journey toward the future of customer engagement.”
Introducing Aktana Copilot
Powered by Tact.ai technology, Aktana today announced Aktana Copilot, an AI assistant on the mobile phone for life sciences field users. Specifically designed for the needs of field sales representatives and medical science liaisons, Aktana Copilot puts market and HCP intelligence in the hands of those users at the moment they need it.
Field teams will receive programmable and intelligence-driven nudges in real-time on mobile devices to simplify call planning with curated insights to drive more personalized and coordinated activity. In addition, recommendations will be presented through conversational AI throughout the user experience saving valuable time that can be repurposed for HCP relationship-building.
Through Aktana Copilot, customers can capture richer and more tailored engagement data which enables Aktana AI to produce more contextual and effective recommendations for users to have better conversations. The dynamic feedback loop improves time-to-value because as the speed in which recommendations improve accelerates, so too does campaign performance.
“Today’s announcements deepen our commitment to transforming customer engagement programs for life sciences organizations of all sizes,” said Derek Choy, founder and Chief Product Officer, Aktana. “The Strategy Suite that we unveiled at the Aktana Innovation Exchange last month will be enhanced with Aktana Copilot, providing a real-time connection between commercial leaders and the field. This can be used to get feedback from the field on tactics impacting their HCPs, and to nudge the field on tactics proven to have the highest impact.”
Aktana Copilot is available globally today and will be enhanced for specific use cases across commercial pharma, medical affairs and medical devices throughout 2024. Aktana will also offer Microsoft Teams users a version of Tact Presenter which is the only Microsoft Teams certified remote detailer for Veeva content.
Connect with Aktana on LinkedIn: www.linkedin.com/company/aktana
Follow @aktana_inc on Twitter: www.twitter.com/aktana_inc
About Aktana
Aktana is the leader in intelligent customer engagement for the global life sciences industry. By ensuring that every customer experience is tailored to individual preferences and needs, Aktana helps life science companies strengthen their relationships with healthcare providers to inspire better patient care. Today, commercial and medical teams from more than 350 brands use Aktana’s AI-enabled Contextual Intelligence Engine to coordinate and optimize personalized omnichannel engagement at scale. More than half of the world’s top 20 pharmaceutical companies are Aktana customers. Headquartered in San Francisco, Aktana has offices in every major biopharma region around the world. For more, visit www.aktana.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231101732293/en/
Contact information
Debby Fry Wilson
deborah.wilson@aktana.com
425-638-9617
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom